Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

GRAd-COV2

From Wikipedia, the free encyclopedia
Vaccine candidate against COVID-19

Pharmaceutical compound
GRAd-COV2
Vaccine description
TargetSARS-CoV-2
Vaccine typeViral vector
Clinical data
Routes of
administration
Intramuscular
Identifiers
CAS Number
Part ofa series on the
COVID-19 pandemic
Scientifically accurate atomic model of the external structure of SARS-CoV-2. Each "ball" is an atom.
Scientifically accurate atomic model of the external structure of SARS-CoV-2. Each "ball" is an atom.
virus iconCOVID-19 portal

GRAd-COV2 is aCOVID-19 vaccine candidate developed by ReiThera Srl andLazzaro Spallanzani National Institute for Infectious Diseases.[2][3] It is based on a novel replication defective Gorilla Adenovirus and encodes for SARS-COV-2 full length prefusion stabilized Spike protein.[2] More specifically, the vector used is the simian group C adenovirus GRAd32, isolated from a captive gorilla, with a genome deleted of the entire E1 and E3 regions and the native E4 region replaced with the E4 orf6 of human adenovirus 5 (hAd5).[4]

References

[edit]
  1. ^"Patent Landscape Report COVID-19-related vaccines and therapeutics"(PDF).
  2. ^ab"GRAd-COV2 Vaccine Against COVID-19".ClinicalTrials.gov.United States National Library of Medicine. 7 January 2021. NCT04528641.
  3. ^"ReiThera Announces its GRAd-COV2 COVID-19 Vaccine Candidate is Well Tolerated and Induces Clear Immune Responses in Healthy Subjects Aged 18–55 Years".ReiThera Srl. Yahoo! Finance. 24 November 2020. Retrieved12 January 2021.
  4. ^Capone S, Raggioli A, Gentile M, Battella S, Lahm A, Sommella A, et al. (April 2021)."Immunogenicity of a new gorilla adenovirus vaccine candidate for COVID-19".Molecular Therapy.29 (8):2412–2423.doi:10.1016/j.ymthe.2021.04.022.PMC 8062434.PMID 33895322.

External links

[edit]
logo
Scholia has a profile forGRAd-COV2(Q98945351).
Development
Classes
Administration
Vaccines
Bacterial
Viral
Protozoan
Helminthiasis
Other
Inventors/
researchers
Controversy
Related
Pre-pandemic
2020
2021
2022
2023
Africa
Northern
Eastern
Southern
Central
Western
Asia
Central/North
East
Mainland China
South
India
By location
Southeast
Malaysia
Philippines
West
Europe
United Kingdom
By location
Eastern
Western Balkans
European Union
EFTA countries
Microstates
North
America
Atlantic
Canada
Caribbean
Countries
British Overseas Territories
Caribbean Netherlands
French West Indies
US insular areas
Central America
United States
responses
By location
Oceania
Australia
New Zealand
South
America
Others
Culture and
entertainment
Arts and
cultural heritage
Education
By country
Sports
By country
By sport
Society
and rights
Social impact
Labor
Human rights
Legal
Minority
Religion
Economic
By country
By industry
Supply and trade
Financial markets
Information
Misinformation
Politics
Political impact
Protests
International relations
Language
Others
Health issues
Medical topics
Testing and
epidemiology
Apps
Prevention
Vaccines
Topics
Authorized
DNA
Inactivated
mRNA
Subunit
Viral vector
Virus-like particles
In trials
Attenuated
DNA
Inactivated
RNA
Subunit
Viral vector
Virus-like particles
Deployment
by location
Africa
Asia
Europe
North America
Oceania
South America
Others
Treatment
Monoclonal antibodies
Small molecule antivirals
Specific
General
Institutions
Hospitals and
medical clinics
Mainland China
Others
Organizations
Health
institutes
Pandemic
institutes
Relief funds
People
Medical
professionals
Researchers
Officials
WHO
By location
Others
Data (templates)
Global
Africa
Americas
Asia
Europe
Oceania
Others
Portals:
Stub icon

This article aboutvaccines orvaccination is astub. You can help Wikipedia byexpanding it.

Stub icon

This article about COVID-19 vaccines is astub. You can help Wikipedia byexpanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=GRAd-COV2&oldid=1247441281"
Categories:
Hidden categories:

[8]ページ先頭

©2009-2025 Movatter.jp